Netherlands· NL-53b4d5333dba
Provera 200 mg, tabletten
A medroxyprogesterone product containing medroxyprogesteronacetaat, registered in Netherlands by Pfizer B.V.. The same ATC class is registered in 8 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Medroxyprogesterone is registered in 8 of 19 countries.
Countries holding a registration under ATC L02AB02 (medroxyprogesterone), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 6 of them publish a price we can compare per daily dose
Medroxyprogesterone · ATC L02AB02
8 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Netherlands
- Polandprice
- Switzerlandprice
- United Statesprice
Price per daily dose
What a daily dose of medroxyprogesterone costs, country by country.
Normalised to the WHO defined daily dose (1 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Medroxyprogesterone · price per daily dose (1 g)
USD · FX 28 Sept 2026
- CH Switzerland$5.69
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- MEDROXYPROGESTERONACETAAT
- Manufacturer
- Pfizer B.V.
- Country
- Netherlands (NL)
- ATC code
- L02AB02
- ATC class
- Medroxyprogesterone
- Defined daily dose
- 1 g, O
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_id10597
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
241 interactions on record for medroxyprogesterone.
Graded by severity as the source publishes them — 21 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Medroxyprogesterone · interactions on record
241 records
- 21 severe
- 213 moderate
- 7 minor
Most severe, free to view
- Tranexamic acidB02AA02severe
- BosentanC02KX01severe
- GriseofulvinD01AA08severe
- GriseofulvinD01BA01severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Medroxyprogesterone in 17 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomMedroxyprogesterone 200mg tabletsPfizer Ltd
- FinlandFarlutalPharmacia Oy
- SwedenProvera 200 mg TablettPfizer AB
- United StatesDepo-ProveraPharmacia & Upjohn Company LLC
- BelgiumDepo-Provera 1000, 1000 mgPfizer
- CzechiaDEPO-PROVERAPfizer, spol. s r.o., Praha
- CanadaAA-MEDROXYAA PHARMA INC
- Japanメドロキシプロゲステロン酢酸エステル協和キリン
Authorised across Europe · EMA
The same active substance is authorised in 22 EEA countries. Names it is sold under:
- Austria · Depocon, Farlutal
- Belgium · Depo-Provera, Provera
- Bulgaria · Фарлутал
- Czechia · Depo-Provera, Provera
- Germany · Depo-Clinovir, Mpa
- Denmark · Depo-Provera, Provera
- Estonia · Farlutal
- Spain · Depo-Progevera, Progevera
- Finland · Farlutal, Provera
- France · Depo Prodasone, Depo Provera
- United Kingdom (Northern Ireland) · Depo-Provera, Medroxyprogesterone Acetate Pfizer
- Croatia · Provera
- Hungary · Depo-Provera, Provera
- Ireland · Depo-Provera, Provera
- Iceland · Depo-Provera
- Italy · Depo-Provera, Farlutal
- Luxembourg · Depo-Provera, Provera
- Latvia · Depo-Provera
- Norway · Depo-Provera, Provera
- Poland · Depo-Provera, Provera
- Portugal · Depo-Provera 150
- Sweden · Depo-Provera, Provera
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/223c856f-918f-4cb7-96d7-d4be60dee61d GET /v1/drugs/223c856f-918f-4cb7-96d7-d4be60dee61d?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tablet",
"route": "Oraal gebruik",
"soort": "RVG",
"source": "cbg_meb",
"smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h10597_smpc.pdf",
"strength": null,
"atc_label": "Medroxyprogesterone",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg10597",
"excipients": [
"CELLULOSE, MICROKRISTALLIJN (E 460(i))",
"DOCUSAATNATRIUM",
"GELATIN, HYDROLYZED (RI)",
"MACROGOL",
"MAGNESIUMSTEARAAT (E 470b)",
"MAÏSZETMEEL",
"NATRIUMBENZOAAT (E 211)",
"NATRIUMZETMEELGLYCOLAAT"
],
"substances": [
"MEDROXYPROGESTERONACETAAT"
],
"leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h10597.pdf",
"authorised_at": "1984/12/12",
"procedure_number": null,
"dispensing_status": "Uitsluitend recept",
"registration_number": "10597",
"additional_monitoring": "N"
}See everything about medroxyprogesterone.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.